MRK's news yesterday was extremely positive and they will stand to grab major market share in lung cancer. If BMY fails to show the same level of survival benefit, MRK will have billions more in sales within a couple of years. I'd rather place my bet on the drug that has already shown great results. Anything can happen in Phase 3, especially in lung cancer. MRK's healthy dividend will grow even bigger from here.